Epigenomics AG (Epigenomics AG) Debt-to-Equity : 0.19 (As of Jun. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Epigenomics AG Debt-to-Equity?

Epigenomics AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.25 Mil. Epigenomics AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.13 Mil. Epigenomics AG's Total Stockholders Equity for the quarter that ended in Jun. 2023 was $2.07 Mil. Epigenomics AG's debt to equity for the quarter that ended in Jun. 2023 was 0.19.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Epigenomics AG's Debt-to-Equity or its related term are showing as below:

EPGNY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.13 Max: 2.93
Current: 0.19

During the past 13 years, the highest Debt-to-Equity Ratio of Epigenomics AG was 2.93. The lowest was 0.02. And the median was 0.13.

EPGNY's Debt-to-Equity is ranked better than
54.82% of 197 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.22 vs EPGNY: 0.19

Epigenomics AG Debt-to-Equity Historical Data

The historical data trend for Epigenomics AG's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Epigenomics AG Debt-to-Equity Chart

Epigenomics AG Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

0.10

0.18

0.02

0.08

Epigenomics AG Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Debt-to-Equity	Get a 7-Day Free Trial															0.06	0.07	0.08	0.10	0.19

Competitive Comparison of Epigenomics AG's Debt-to-Equity

For the Diagnostics & Research subindustry, Epigenomics AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Epigenomics AG's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Epigenomics AG's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Epigenomics AG's Debt-to-Equity falls into.

Epigenomics AG Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Epigenomics AG's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.343	+	0.548)	/	10.775
	=	0.08

Epigenomics AG's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.251	+	0.134)	/	2.068
	=	0.19

Epigenomics AG (OTCPK:EPGNY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Epigenomics AG Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Epigenomics AG's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Epigenomics AG (Epigenomics AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Epigenomics AG (OTCPK:EPGNY) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

EPGNF:USA ECX:Germany

Address

Geneststrasse 5, Berlin, BB, DEU, 10829

Website

https://www.epigenomics.com

Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.

Epigenomics AG (Epigenomics AG) Headlines

From GuruFocus

Encode Ideas, L.P. to host Virtual 1x1 Webinar with Epigenomics AG (ECX.DE, EPGNF) on Tuesday, July 28th at 10:30 AM ET

By ACCESSWIRE ACCESSWIRE • 07-23-2020